Vantia Therapeutics

Scroll
Investment area
Novo Ventures
Region
Europe
Date of investment
March 2008
Website
http://www.vantia.com/

Vantia Therapeutics develops small molecule agonists of vasopressin receptors. The lead asset is in phase 3 clinical development for the treatment of nocturia.

Novo Holdings uses cookies to ensure that we give you the best experience on our website. Read more